Which antibiotics precipitate hemolysis in patients who are deficient in glucose‑6‑phosphate dehydrogenase (G6PD)?

Antibiotics That Precipitate Hemolysis in G6PD-Deficient Patients

The antibiotics most clearly associated with hemolysis in G6PD deficiency are sulfonamides (including sulfamethoxazole-trimethoprim), nitrofurantoin, dapsone, and chloramphenicol, though recent evidence suggests quinolones may pose less risk than traditionally thought.

High-Risk Antibiotics

Definitively Avoid:

• Sulfonamides (including sulfamethoxazole-trimethoprim) - Listed as precipitating factors in guidelines 1, though prophylactic dosing may be safer than therapeutic doses 2
• Nitrofurantoin - Established trigger 3
• Dapsone - Well-documented oxidant drug 1, 3
• Chloramphenicol - Known hemolytic trigger 3

Controversial/Lower Risk:

Quinolones (Ciprofloxacin, Levofloxacin, Ofloxacin, Moxifloxacin):

• Traditionally listed on avoidance lists, but the most recent large-scale evidence challenges this
• A 2026 nationwide study of 465,083 antibiotic dispensations in 64,861 G6PD-deficient patients found no statistically significant increased risk of hemolysis with quinolones versus penicillins (adjusted OR 1.29,95% CI 0.92-1.77, P=0.12) 4
• However, isolated case reports exist (e.g., ofloxacin-induced hemolysis) 5
• Clinical approach: While population-level risk appears low, individual susceptibility varies with G6PD variant severity, concurrent oxidative stressors (active infection), and age (very young children may be more vulnerable) 4

Metronidazole and Tetracycline:

• A 2026 case report documented severe hemolysis (hemoglobin drop of 4.4 g/dL) within hours of starting H. pylori quadruple therapy containing metronidazole and tetracycline 6
• These are not traditionally on high-risk lists but warrant caution in combination regimens

Beta-lactams (Penicillins, Amoxicillin):

• Generally considered safe
• One case report suggests possible amoxicillin-associated hemolysis, though causality uncertain 7
• Used as the active comparator (safe control) in the large quinolone safety study 4

Critical Clinical Considerations

Important Caveats:

1. G6PD variant severity matters: Patients with severe enzyme deficiency (Class I-II variants) are at higher risk than those with milder deficiency
2. Concurrent oxidative stress amplifies risk: Active infections, other oxidant drugs, or fava bean exposure can trigger hemolysis even with "safer" antibiotics 4
3. Dose-dependent effects: Prophylactic doses (e.g., SMX-TMP for PCP prophylaxis) appear safer than therapeutic doses 2

Before Prescribing Antibiotics in Known G6PD Deficiency:

• Identify the specific G6PD variant if possible (severity varies dramatically)
• Assess for concurrent oxidative stressors (active infection, other medications)
• Consider age (neonates and young children more vulnerable)
• Methylene blue cannot be used to treat methemoglobinemia in G6PD deficiency as it worsens hemolysis 1

Monitoring After Antibiotic Initiation:

Watch for hemolysis signs within hours to 2 weeks:

• Dark urine (hemoglobinuria)
• Jaundice
• Pallor
• Fatigue, tachycardia, dyspnea
• Acute drop in hemoglobin
• Elevated LDH, indirect bilirubin, low haptoglobin